Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMRANASDAQ:EVLONASDAQ:SCPSNASDAQ:STAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMRAComera Life Sciences$0.00$0.00▼$0.06$6K0.716,537 shs118,900 shsEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.06$9K1.0511,590 shs187 shsSCPSScopus BioPharma$0.00$0.00$0.00▼$0.01$13K-0.272,286 shs25 shsSTABStatera Biopharma$0.00$0.00▼$0.13$5K0.169,977 shsN/AReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMRAComera Life Sciences0.00%0.00%0.00%0.00%-99.51%EVLOEvelo Biosciences0.00%0.00%0.00%0.00%-98.87%SCPSScopus BioPharma0.00%0.00%0.00%0.00%-81.25%STABStatera Biopharma0.00%0.00%0.00%0.00%-85.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMRAComera Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ASTABStatera BiopharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMRAComera Life Sciences 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/ASCPSScopus BioPharma 0.00N/AN/AN/ASTABStatera Biopharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMRAComera Life Sciences$1.00M0.00N/AN/AN/ANaNEVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/AN/ASTABStatera BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMRAComera Life Sciences-$18MN/A0.00N/AN/AN/AN/AN/AN/AEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A4/25/2025 (Estimated)SCPSScopus BioPharma-$11.61MN/A0.00∞N/AN/AN/AN/AN/ASTABStatera BiopharmaN/AN/A0.00N/AN/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMRAComera Life SciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/ASCPSScopus BioPharmaN/AN/AN/AN/AN/ASTABStatera BiopharmaN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMRAComera Life SciencesN/AEVLOEvelo Biosciences0.31%SCPSScopus BioPharmaN/ASTABStatera BiopharmaN/AInsider OwnershipCompanyInsider OwnershipCMRAComera Life Sciences8.90%EVLOEvelo Biosciences1.02%SCPSScopus BioPharma5.10%STABStatera Biopharma5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataSCPSScopus BioPharma942.08 million39.94 millionNot OptionableSTABStatera Biopharma2053.30 millionN/ANot OptionableSTAB, SCPS, EVLO, and CMRA HeadlinesRecent News About These CompaniesFed-up Minnesotans warn Tim Walz uses Midwest charm to drive far-left policies: ‘He will stab you in the back’August 10, 2024 | nypost.comThe Scientific and Technical Advisory BodyMay 22, 2024 | unesco.orgDog-walking NY couple turns table on would-be mugger who was hospitalized with stab wounds: videoMay 19, 2024 | foxnews.comPocket Bravery developer Statera Studio announces 2D platform fighter Shield Strike for PCMay 18, 2024 | gematsu.comBridgend: Wife begged ex-councillor to end stab attack - courtMay 8, 2024 | bbc.co.ukStatera BioPharma Inc Ordinary SharesApril 18, 2024 | morningstar.comCRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICAApril 12, 2024 | finance.yahoo.comArrests after man found with serious stab injuriesApril 7, 2024 | bbc.comPolice appeal after man found with stab injuriesApril 4, 2024 | bbc.comAEON Biopharma Inc.February 25, 2024 | wsj.comMereo BioPharma Group PLC ADR (MREO)January 30, 2024 | investing.comCrookes curry house knife used to stab teenager to deathDecember 14, 2023 | bbc.comLeeds stab death: Police name victim of Chapeltown attackDecember 9, 2023 | bbc.comTwo boys, 12, in court charged with Wolverhampton stab murderNovember 25, 2023 | bbc.co.ukWolverhampton: Two boys, 12, arrested over stab murder of manNovember 25, 2023 | bbc.co.ukARCA biopharma Inc ABIONovember 11, 2023 | morningstar.comCornell University student threatened to stab and rape Jewish students and ‘shoot up’ school, prosecutors sayNovember 10, 2023 | nbcnews.comPOINT Biopharma Global Inc Ordinary Shares PNTOctober 31, 2023 | morningstar.comElianne Andam died from ‘multiple stab wounds’ in ‘brutal’ attackOctober 29, 2023 | nypost.comNewport News mother dies by suicide while serving sentence for stabbing children, killing 1: HRRJOctober 27, 2023 | wtkr.comMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNVIDIA vs Qualcomm: Which Is the Better Buy for Q2?By Sam Quirke | April 3, 2025View NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?IAMGOLD Stock Climbs as Turnaround Story Gains TractionBy Jeffrey Neal Johnson | April 11, 2025View IAMGOLD Stock Climbs as Turnaround Story Gains TractionWhich Healthcare Stock Is the Best Buy Right Now?By Nathan Reiff | March 31, 2025View Which Healthcare Stock Is the Best Buy Right Now?AT&T and Verizon: 2 Telecom Titans for a Tariff-Proof PlayBy Jeffrey Neal Johnson | March 31, 2025View AT&T and Verizon: 2 Telecom Titans for a Tariff-Proof PlayBerkshire Hathaway Gains Defy Stock Market Slump By Jeffrey Neal Johnson | April 1, 2025View Berkshire Hathaway Gains Defy Stock Market Slump STAB, SCPS, EVLO, and CMRA Company DescriptionsComera Life Sciences NASDAQ:CMRAComera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.Evelo Biosciences NASDAQ:EVLO$0.0005 0.00 (0.00%) As of 09:30 AM EasternEvelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Scopus BioPharma NASDAQ:SCPS$0.0003 0.00 (0.00%) As of 04/23/2025Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.Statera Biopharma NASDAQ:STABStatera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
